Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Dapagliflozin Effects on Epicardial Fat
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT02235298
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 86
- Registration Number
- NCT02234440
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India
Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02231931
- Locations
- 🇩🇪
352.2082.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02230995
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach an der Riss, Germany
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02220647
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 95
- Registration Number
- NCT02221414
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02221401
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02221180
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- DiabetesDiabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 108
- Registration Number
- NCT02205528
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Manassas, Virginia, United States
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02202161
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.